SIREN : 795920032
LABORATOIRES COLUXIA is a French company founded 67 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in DIGOIN (71160), this company of category ETI shows in 2024 a revenue of 3.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 519 490 € | 4 290 747 € | 4 658 559 € | 3 635 863 € | 2 897 733 € | 3 060 485 € | 2 861 348 € | 3 320 712 € | 3 066 394 € |
| Net income | 394 156 € | 601 733 € | 1 027 083 € | 624 264 € | 355 199 € | 494 927 € | 497 769 € | 676 919 € | 677 824 € |
| EBITDA | 653 447 € | 1 127 337 € | 1 473 366 € | 994 805 € | 504 771 € | 718 638 € | 686 731 € | 1 018 409 € | 811 247 € |
| Net margin | 11.2% | 14.0% | 22.0% | 17.2% | 12.3% | 16.2% | 17.4% | 20.4% | 22.1% |
In 2024, LABORATOIRES COLUXIA achieves revenue of 3.5 M€. Revenue is growing positively over 9 years (CAGR: +1.7%). Significant drop of -18% vs 2023. After deducting consumption (938 k€), gross margin stands at 2.6 M€, i.e. a rate of 73%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 653 k€, representing 18.6% of revenue. Warning negative scissor effect: despite revenue change (-18%), EBITDA varies by -42%, reducing margin by 7.7 pts. This reflects costs rising faster than revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 394 k€, i.e. 11.2% of revenue. This profit can be retained or distributed to shareholders.
3 519 490 €
2 581 059 €
653 447 €
456 648 €
394 156 €
18.6%
The debt ratio (= Financial debt / Equity x 100) stands at 26%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 73%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.6 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 16.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
25.701%
72.517%
16.499%
1.62
39.3%
In 2024, the debt ratio of LABORATOIRES COLUXIA (25.70) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of LABORATOIRES COLUXIA (72.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of LABORATOIRES COLUXIA (1.62) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 909.36. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.4x. Danger: operating income does not cover interest charges, unsustainable situation.
909.363
0.409
In 2024, the liquidity ratio of LABORATOIRES COLUXIA (909.36) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of LABORATOIRES COLUXIA (0.4x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 45 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 30 days. The company must finance 15 days of gap between collections and payments. Inventory turnover is 41 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 285 days of revenue, i.e. 2.8 M€ to permanently finance. Over 2016-2024, WCR increased by +379%, requiring additional financing.
2 785 676 €
45 j
30 j
41 j
285 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 78 641€ to 241 713€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare LABORATOIRES COLUXIA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of LABORATOIRES COLUXIA in 2024 is 3.5 M€.
Yes, LABORATOIRES COLUXIA generated a net profit of 394 k€ in 2024.
The headquarters of LABORATOIRES COLUXIA is located in DIGOIN (71160), in the department Saone-et-Loire.
The tax return of LABORATOIRES COLUXIA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
LABORATOIRES COLUXIA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.